<u></u>

C

PTO/SB/05 (11-00) Approved for use through 10/31/2002. OMB 0651-0032 U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Attorney Docket No. UTILITY Yu-Ping Xia First Inventor

PATENT APPLICATION TRANSMITTAL

Methods of Treating Inflammatory Skin Diseases Title

EJ915220988US Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents ADDRESS TO: **Box Patent Application** APPLICATION ELEMENTS Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (Submit an original and a duplicate for fee processing) Applicant claims small entity status. (if applicable, all necessary) Computer Readable Form (CRF) See 37 CFR 1.27. 119 [Total Pages Specification b. Specification Sequence Listing on: (preferred arrangement set forth below) X - Descriptive title of the invention CD-ROM or CD-R (2 copies); or - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D paper - Reference to sequence listing, a table, Statements verifying identity of above copies or a computer program listing appendix ACCOMPANYING APPLICATION PARTS - Background of the Invention - Brief Summary of the Invention Assignment Papers (cover sheet & document(s)) - Brief Description of the Drawings (if filed) 9. Power of 37 CFR 3.73(b) Statement - Detailed Description Attorney (when there is an assignee) - Claim(s) - Abstract of the Disclosure English Translation Document (if applicable) Copies of IDS 65 [Total Sheets Information Disclosure Drawing(s) (35 U.S.C. 113) 4. X Citations Statement (IDS)/PTO-1449 12. [Total Pages Preliminary Amendment 5. Oath or Declaration 13. Return Receipt Postcard (MPEP 503) Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) 14. X (Should be specifically itemized) a. Certified Copy of Priority Document(s) (if foreign priority is claimed) DELETION OF INVENTOR(S) 15. Request and Certification under 35 U.S.C. 122 Signed statement attached deleting inventor(s) (b)(2)(B)(i). Applicant must attach form PTO/SB/35 named in the prior application, see 37 CFR 16. or its equivalent. 1.63(d)(2) and 1.33(b). Other: unexecuted Declaration and Power of Attorney 17. X Application Data Sheet. See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, of prior application No.PCT/US00/14142 or in an Application Data Sheet under 37 CFR 1.76: Continuation-in-part (CIP) Not Yet Known Divisional Continuation Not Yet Known Group Art Unit: __ For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Correspondence address below (Insert Customer, No. or Attach bar, code label here) Customer Number or Bar Code Label Linda O. Palladino Regeneron Pharmaceuticals, Inc. Name 777 Old Saw Mill River Road 10591 Zip Code New York <u>Address</u> State Tarrytown 914-345-7721 914-345-7400 Fax City United States Telephone Country Registration No. (Attorney/Agent) 45,636 Linda O. Palladino 1/31/01 Name (Print/Type) Date LND

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.





PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 4,822.00

C		
Application Number	Not Yet Known	
Filing Date	Filed Herewith	_
First Named Inventor	Yu-Ping Xia	
Examiner Name	Not Yet Known	
Group Art Unit	Not Yet Known	
Attorney Docket No.	REG 710B	

METHOD OF PAYMENT	FEE CALCULATION (continued)				
	3. ADDITIONAL FEES				
Deposit	Large Small				
Account Number 18-0650	Entity Entity Fee Fee Fee Fee Fee Description F Code (\$) Code (\$)	ee Paid			
Regeneron Pharmaceuticals,	105 130 205 65 Surcharge - late filing fee or oath				
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet				
Applicant claims small entity status.	139 130 139 130 Non-English specification				
See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination				
2. X Payment Enclosed: X Check Credit card Money Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action				
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action				
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month				
Large Entity Small Entity	116 390 216 195 Extension for reply within second month				
Fee Fee Fee Fee Description	117 890 217 445 Extension for reply within third month	-			
0040 (0) 0040 (0)	118 1,390 218 695 Extension for reply within fourth month				
101 710 201 355 Utility filing fee 710.	128 1,890 228 945 Extension for reply within fifth month				
107 490 207 245 Plant filing fee	119 310 219 155 Notice of Appeal				
108 710 208 355 Reissue filing fee	120 310 220 155 Filing a brief in support of an appeal				
114 150 214 75 Provisional filing fee	121 270 221 135 Request for oral hearing				
	138 1,510 138 1,510 Petition to institute a public use proceeding				
SUBTOTAL (1) (\$) 710.	140 110 240 55 Petition to revive - unavoidable				
2. EXTRA CLAIM FEES Fee from	141 1,240 241 620 Petition to revive - unintentional				
Extra Claims below Fee Paid	142 1,240 242 620 Utility issue fee (or reissue)				
Total Claims $109 - 20^{-2} = 89 \times 18. = 1.602$	143 440 243 220 Design issue fee				
Independent 31 - 3** = 28 x 80. = 2,240	144 600 244 300 Plant issue fee				
Multiple Dependent 270. = 270.	122 130 122 130 Petitions to the Commissioner				
4 F-44 O	123 50 123 50 Processing fee under 37 CFR 1.17(q)				
Large Entity Small Entity Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt				
Code (\$) Code (\$) 103	581 40 581 40 Recording each patent assignment per property (times number of properties)				
102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection				
104 270 204 135 Multiple dependent claim, if not paid	(37 CFR § 1.129(a)) 149 710 249 355 For each additional invention to be				
109 80 209 40 ** Reissue independent claims over original patent	examined (37 CFR § 1.129(b))				
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)	<u>-</u>			
and over original patent	169 900 169 900 Request for expedited examination of a design application				
SUBTOTAL (2) (\$) 4,112.	Other fee (specify)				
**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)				

SUBMITTED BY			Complete (if applicable)		
Name (Print/Type)	Linda O. Palladino	Registration No. (Attorney/Agent)	45,636	Теlерһопе	914-345-7400
Signature	Kadao. Polla	deno		Date	1/31/01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.